Dr. Rahul Kushwah reports

PREDICTMEDIX AI INC - 2025 YEAR END CORPORATE UPDATE

Predictmedix AI Inc. has concluded 2025, having delivered a year of disciplined execution across technology development, global investor engagement and strategic advancement -- positioning the company for a pivotal growth phase in 2026 at the convergence of artificial intelligence, quantum-inspired computation and digital health care.

Throughout 2025, Predictmedix AI enhanced the performance, scalability and real-world effectiveness of its AI-driven health screening platforms while pioneering quantum-inspired computational enhancements. By leveraging hybrid quantum-classical algorithms, the company has achieved sharper noise reduction, improved signal clarity and more accurate screening across diverse populations -- all while running efficiently on standard computing hardware without specialized quantum devices. These efforts are designed to elevate signal clarity, robustness and adaptability beyond conventional AI approaches, establishing a strong trajectory as the company enters 2026 with momentum, validated deployments and increasing market visibility.

SmartHealth AI stations

In 2025, Predictmedix AI surpassed 500,000 real-world scans, validating the scalability, resilience and commercial readiness of its SmartHealth AI stations across diverse environments and populations. As the first large-scale deployment of the company's proprietary core AI engine, SmartHealth has proved the effectiveness of contactless, validated screening while continuously generating high-value real-world data.

This expanding data set has strengthened model performance and supports the advancement of quantum-inspired enhancements. Using cutting-edge hybrid quantum-classical simulations, the SmartHealth AI stations can model image noise and variability across diverse lighting, skin tones and occlusions, delivering sharper detection clarity and reduced bias, all in real time on standard hardware.

Global investor engagement and European road shows

During 2025, Predictmedix AI significantly expanded engagement with the global investment community. The company headlined a targeted European investor road show with events in Hungary, Croatia and Serbia, engaging institutional investors, family offices and strategic capital partners across central and southeastern Europe. These engagements increased awareness of Predictmedix AI's proprietary core AI engine, multivertical growth strategy and global commercialization road map.

The company also presented at the MK Investment Conference in Munich, Germany, further strengthening visibility with European institutional investors and reinforcing Predictmedix AI's positioning as a next-generation AI health care technology company.

Collectively, these initiatives supported increased institutional interest and participation in company financings, reinforcing confidence in Predictmedix AI's execution strategy and long-term value creation.

Execution of a multivertical growth strategy

Predictmedix AI continued disciplined execution of its multivertical strategy built around a single proprietary core AI engine powering three complementary growth verticals:

• SmartHealth AI stations for workplace, institutional and health care screening;
• Clinical-trial AI platforms focused on patient matching, simulation and trial optimization;
• Consumer mobile applications for scalable vital and wellness screening.

This integrated architecture allows Predictmedix AI to deploy shared data sets, adaptive learning systems and quantum-inspired computational approaches across multiple markets, creating operational leverage and long-term competitive differentiation as the platform scales. These applications leverage a unified intelligence framework shared with SmartHealth deployments, enabling the consistent application of advanced AI and quantum-inspired computational intelligence across both stationary and mobile platforms.

Strategic investments in capability and expertise

To accelerate innovation and execution, Predictmedix AI has engaged key advisers and consultants across technology development, strategic guidance and business development initiatives. As part of these strategic collaborations, the company plans to issue 12.3 million common shares to nine consultants, further aligning contributors with long-term value creation and supporting the continued advancement of its technology platforms and strategic priorities.

Looking ahead: 2026 -- the next evolution of AI-driven health care

Entering 2026, Predictmedix AI is positioned to build on validated platforms, expanding data sets and increasing commercial traction while advancing quantum-inspired AI capabilities across its health screening ecosystem.

Key priorities include:

• Scaling SmartHealth AI station deployments globally;
• Expanding adoption of mobile digital health solutions;
• Accelerating U.S. and international commercialization;
• Advancing recurring revenue opportunities across AI platforms.

In 2026, Predictmedix AI will further integrate quantum-inspired computational algorithms into both stationary and mobile platforms, using hybrid quantum-classical approaches to optimize signal fidelity, reduce detection bias and increase screening confidence. These innovations aim to deliver faster, more precise and more inclusive health screening across global populations, solidifying Predictmedix AI's leadership at the intersection of AI, quantum-inspired computation and health care.

As health care increasingly demands higher levels of precision, adaptability and trust across diverse populations, Predictmedix AI is advancing toward a new generation of AI-driven screening -- where quantum-inspired computation enhances real-world performance and global scalability.

About Predictmedix AI Inc.

Predictmedix AI is an emerging provider of rapid health screening and remote patient care solutions globally. The company's Smarthealth AI stations -- powered by proprietary artificial intelligence -- use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vitals, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes.

We seek Safe Harbor.